FiercePharma

BioTime Submits Protocol for Initiation of Human Clinical Trials of Renevia™ in Europe

ALAMEDA, Calif.--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced it has submitted a Clinical ...
FiercePharma

BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.33 Million Grant From Israel’s Office of the Chief Scientist

BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.33 Million Grant From Israel’s Office of the Chief Scientist BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. ...
Business Wire

BioTime, Inc. and the University of California System Sign Cell Transfer Agreement for Human Embryonic Stem Cell Lines

BioTime develops and markets research products in the field of stem cells and regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. BioTime’s therapeutic product ...
Business Wire

BioTime Awarded a $4.7 Million Research Grant from the California Institute for Regenerative Medicine

BioTime Awarded a $4.7 Million Research Grant from the California Institute for Regenerative Medicine Grant to Fund Expansion of BioTime’s ACTCellerate™ Human Embryonic Stem Cell Product Development ...
FierceBiotech

BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel’s Office of the Chief Scientist

BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel’s Office of the Chief Scientist BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd.